<DOC>
	<DOCNO>NCT02027753</DOCNO>
	<brief_summary>Primary Objective : To investigate efficacy ( HbA1c ) 6 month add basal insulin therapy ( insulin glargine ) dipeptidyl peptidase-IV ( DPP-IV ) metformin plus minus sulphonylurea Secondary Objectives : 1 . To assess efficacy add insulin glargine 2 . To assess insulin dose 3 . Safety</brief_summary>
	<brief_title>Efficacy Safety Insulin Glargine Patients With Type 2 Diabetes With Inadequate Control DPP-4 Inhibitor Therapy</brief_title>
	<detailed_description>28 week ( Screening : About 2 weeks/Treatment : 24 week ( 6 month ) /Follow-up : 2 week )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 Diabetes mellitus ≥ 20 age Patients treat DPP 4 least 3 month inform consent metformin plus minus sulphonylurea inadequately control HbA1c ≥ 7.5 % Be able voluntarily agree participate study sign write informed consent Exclusion criterion : Diabetes patient Type 2 ( eg . Type 1 Diabetes mellitus , pancreatic disease , secondary diabetes ) HbA1c &gt; 11 % screen History continuous basal insulin treatment within 1 year screen History diabetic acidosis ( include ketoacidosis ) within 1 year screen History myocardial infarct , stroke heart failure relate admission within 3 month screen History drug alcoholic abuse within 6 month screen Weight change ≥ 5 kg within 3 month screen History hypoglycemic unawareness Systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg regardless take antihypertensive , uncontrolled hypertension Active malignant cancer , major systemic disease , clinically significant diabetic retinopathy , macular edema necessitate laser treatment , abnormal clinical find physical examination , lab analysis , electrocardiogram vital sign , regard prevent safe completion clinical study make efficacy assessment difficult investigator coinvestigator screen Pregnant lactate woman Women child bear potential ( Premenopause surgically infertile within 3 month screen ) match two condition : Negative serum pregnancy test screen Using medically proven effective contraceptive method Hypersensitivity investigational drug Lab find screening : Abnormal liver function : Alanine transaminase Alkaline phosphatase &gt; 3 time upper limit normal range Renal insufficiency : Men serum Cr ≥ 1.5 mg/dL ( ≥ 133µmol/L ) , woman serum Cr ≥ 1.4 mg/dL ( ≥ 124 µmol/L ) Use antiobese drug within 3 month screen Has use drug influence glucose metabolism ( systemic corticosteroid , thyroid hormone ) within 3 month screen possibility use drug investigational period Has participate clinical study investigational drug within 3 month screen Considered physically psychologically appropriate participate clinical study investigator Not willing comply schedule visit , selfinject insulin , selfmonitor blood glucose level The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>